It has been demonstrated that the injection of purified or ex vivo cultured CD4+CD25+Foxp3+ nTregs significantly reduces GVHD [164, 165] and, in combination with bone marrow transplantation, inhibit alloreactive CD4+ and CD8+ T cells and prolong allograft survival [166, 167]. Here, CD4 is linked to graft versus host disease.